TORONTO, ONTARIO–(Marketwired – Dec. 24, 2015) – Mettrum Health Corp. (“Mettrum” or the “Company“) (TSX VENTURE:MT), a fully integrated provider of premium cannabis products, is pleased to announced that, effective December 23, 2015, the Company has been granted a license to sell cannabis extracts. As announced on August 31, 2015, Mettrum was initially granted a supplemental license for the production of cannabis extracts. Mettrum is the second company in the industry to have been awarded a license for the production and sale of cannabis extracts.
“Securing this license is a continuation of our strategy of providing cannabis products, in a variety of formats. Our clients will be able to rely upon a selection of cannabis oils representing each band of the Mettrum Spectrum including our CBD strains. Cannabis extracts provide a level of standardization that cannot be achieved in the flower form, and in some cases, it is a more convenient consumption method,” said Michael Haines, Chief Executive Officer of Mettrum. “We are very excited about this new phase for the industry and we look forward to continuing our role as a market leader, and provider, of high quality, cannabis products.”
Mettrum anticipates announcing its updated product portfolio in early January, based on the addition of cannabis extracts, and commence sales of its full product line shortly thereafter.
About Mettrum Health Corp.
Mettrum Health Corp. is a Tier 1 Industry Issuer listed on TSX Venture Exchange. Mettrum Ltd., a wholly owned subsidiary of the Company, is a Toronto-based company and a licensed producer of medical cannabis under the Marihuana for Medical Purposes Regulations (Canada) issued pursuant to the Controlled Drugs and Substances Act (Canada) (the “MMPR“), which came into effect on October 1, 2013. Mettrum received its first license from Health Canada under the MMPR on November 1, 2013 and began production of medical cannabis at its first production facility in Bowmanville, Ontario. Mettrum received its second license from Health Canada under the MMPR on December 11, 2014 for its other wholly-owned subsidiary, Agripharm Corp., at Mettrum Creemore facility in Clearview, Ontario. Mettrum received its third license from Health Canada under the MMPR on December 17, 2015 for Mettrum Ltd. at its new 60,000 square foot production and distribution facility in Bowmanville, Ontario. With the Company’s three licenses, Mettrum is a leading producer and vendor of medical cannabis under the MMPR system.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; delay or failure to receive board, shareholder or regulatory approvals; and the results of operations. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company and Mettrum disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this Press release.